Trial · NCT03110770
Adverse events290
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
121 to 140 of 290
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 0 | 30 | |
| other | Hypertension | Vascular disorders | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | 1 | 30 | |
| other | Hypertension | Vascular disorders | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | 3 | 30 | |
| other | Hypertension | Vascular disorders | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 26 | 1,162 | |
| other | Hypertension | Vascular disorders | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | 27 | 1,161 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 1 | 30 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | 0 | 30 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | 1 | 30 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 72 | 1,162 | |
| other | Eosinophilia | Blood and lymphatic system disorders | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | 69 | 1,161 | |
| other | Pyrexia | General disorders | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 0 | 30 | |
| other | Pyrexia | General disorders | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | 0 | 30 | |
| other | Pyrexia | General disorders | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | 1 | 30 | |
| other | Pyrexia | General disorders | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 63 | 1,162 | |
| other | Pyrexia | General disorders | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | 66 | 1,161 | |
| other | Nasopharyngitis | Infections and infestations | Part A, Group 1: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 0 | 30 | |
| other | Nasopharyngitis | Infections and infestations | Part A, Group 2: VRC-ZKADNA090-00-VP (4 mg), 4 Injections | 0 | 30 | |
| other | Nasopharyngitis | Infections and infestations | Part A, Group 3: VRC-ZKADNA090-00-VP (8 mg), 4 Injections | 0 | 30 | |
| other | Nasopharyngitis | Infections and infestations | Part B, Group 4: VRC-ZKADNA090-00-VP (4 mg), 2 Injections | 72 | 1,162 | |
| other | Nasopharyngitis | Infections and infestations | Part B, Group 5: Placebo (VRC-PBSPLA043-00-VP), 2 Injections | 75 | 1,161 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03110770/events?page=7